Coronavirus Disease 2019 (COVID-19) is upsetting the world and innovative therapeutic solutions are needed in an attempt to counter this new pandemic. Great hope lies in vaccines, but drugs to cure the infected patient are just as necessary. In the most severe forms of the disease, a cytokine storm with neuroinflammation occurs, putting the patient's life at serious risk, with sometimes long-lasting sequelae. Palmitoylethanolamide (PEA) is known to possess anti-inflammatory and neuroprotective properties, which make it an ideal candidate to be assumed in the earliest stage of the disease. Here, we provide a mini-review on the topic, pointing out phospholipids consumption in COVID-19, the possible development of an antiphospholipid syndrome secondary to SARS-CoV-2 infection, and reporting our preliminary single-case experience concerning to a 45-year-old COVID-19 female patient recently treated with success by micronized / ultramicronized PEA.

2019 年冠状病毒病 (COVID-19) 正在困扰世界，需要创新的治疗解决方案来对抗这种新的大流行病。很大的希望在于疫苗，但治愈感染患者的药物同样是必需的。在最严重的疾病形式中，会发生细胞因子风暴和神经炎症，使患者的生命面临严重风险，有时会留下长期后遗症。已知棕榈酰乙醇胺 (PEA) 具有抗炎和神经保护特性，这使其成为疾病早期阶段的理想候选药物。在这里，我们对该主题进行了简要回顾，指出了 COVID-19 中的磷脂消耗，SARS-CoV-2 感染继发的抗磷脂综合征的可能发展，